Patent classifications
C07C309/29
SALTS/COCRYSTALS OF (R)-N-(4-CHLOROPHENYL)-2-((1S,4S)-4-(6-FLUOROQUINOLIN-4-YL)CYCLOHEXYL)PROPANAMIDE
The present disclosure relates to amorphous and crystalline forms of (R)—N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoro-quinolin-4-yl)cyclohexyl)propanamide and its salts/cocrystals, solvates, and/or hydrates, processes for their production, pharmaceutical compositions comprising them, and methods of treatment using them.
SHORT-ACTING BENZODIAZEPINE SALTS AND THEIR POLYMORPHIC FORMS
The invention relates to besylate salts of the compound of formula (I):
##STR00001##
Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.
SHORT-ACTING BENZODIAZEPINE SALTS AND THEIR POLYMORPHIC FORMS
The invention relates to besylate salts of the compound of formula (I):
##STR00001##
Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.
NOVEL COMPOUNDS
Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of disease or conditions in which HNE is implicated
NOVEL COMPOUNDS
Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of disease or conditions in which HNE is implicated
LIGHT-ABSORBING MATERIAL, RECORDING MEDIUM USING THE SAME, INFORMATION RECORDING METHOD AND INFORMATION READING METHOD
A light-absorbing material includes a compound represented by the formula (1) below. In the formula (1), L.sup.1 to L.sup.3 are each independently represented by the formula (2) or (3) below:
##STR00001##
Nitrogen-containing Derivative of Substituted Phenol Hydroxy Acid Ester, and Preparation and Use Thereof
A nitrogen-containing derivative of substituted phenol hydroxyl acid ester is represented by formula (I). A salt of the compound of formula (I) has good water solubility, and in vivo, can rapidly and completely release substituted phenols having a pharmacological effect, which can improve the water solubility of substituted phenols, rapidly exert the pharmacological effects of substituted phenols in vivo, and has good safety. The method for preparing the above-mentioned compound is provided. This compound can also be used in the preparation of drugs that produce anaesthesia and/or sedative and hypnotic effects on humans and animals.
##STR00001##
PHENYL PYRROLE AMINOGUANIDINE SALTS AND FORMULATIONS
The disclosure relates to oral formulations for gastric delivery of a pharmaceutically acceptable salt of a phenyl pyrrole aminoguanidine compound.
5-HT3 RECEPTOR MODULATOR, THE CRYSTALLINE FORM, METHODS OF MAKING, AND USE THEREOF
The present disclosure discloses free form or base and salts of compound of formula (I). Said salts include adipate, benzenesulphonate, hydrobromide, fumarate, benzoate, methanesulfonate, L-malate, d-glyconate, sorbate, phosphate, sulfate, L-tartrate, p-methylbenzenesulphonate, citrate, hydrochloride, ethanesulfonate, 1-hydroxy-2-naphthoate, succinate, acetate, glutarate or L-pyroglutamate. The present disclosure also discloses the crystals of free form and above salts.
5-HT3 RECEPTOR MODULATOR, THE CRYSTALLINE FORM, METHODS OF MAKING, AND USE THEREOF
The present disclosure discloses free form or base and salts of compound of formula (I). Said salts include adipate, benzenesulphonate, hydrobromide, fumarate, benzoate, methanesulfonate, L-malate, d-glyconate, sorbate, phosphate, sulfate, L-tartrate, p-methylbenzenesulphonate, citrate, hydrochloride, ethanesulfonate, 1-hydroxy-2-naphthoate, succinate, acetate, glutarate or L-pyroglutamate. The present disclosure also discloses the crystals of free form and above salts.